[FG] Trendelenburg Marten

Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/NXI.0000000000200361.

Kruta, Jan et al. (2024) ‘Machine learning for precision diagnostics of autoimmunity’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-76093-7.

Moser, Stephan et al. (2024) ‘Association of Endothelial Cell Activation with Acute Kidney Injury during Coronary Angiography and the Influence of Recombinant Human C1 Inhibitor—A Secondary Analysis of a Randomized, Placebo-Controlled, Double-Blind Trial’, Biomedicines, 12. Available at: https://doi.org/10.3390/biomedicines12091956.

Eckardt, Henrik et al. (2024) ‘Major low-energy trauma results in non-specific immunoglobulin generation without evidence for specific autoantibody production: A prospective cohort study’, Scandinavian Journal of Immunology, 99. Available at: https://doi.org/10.1111/sji.13368.

Isayeva, Ganna et al. (2024) ‘Diagnostic and prognostic value of mannan-binding lectin associated protein (MAp19) for functionally relevant coronary artery disease’, Clinica Chimica Acta, 558. Available at: https://doi.org/10.1016/j.cca.2024.119668.

Oechtering, Johanna et al. (2024) ‘Complement Activation Is Associated With Disease Severity in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(2). Available at: https://doi.org/10.1212/NXI.0000000000200212.

Kleer, Jessica S. et al. (2024) ‘Factor H-related protein 1 in systemic lupus erythematosus’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1447991.

Mihailovic, Jelena et al. (2023) ‘Worse cardiovascular and renal outcome in male SLE patients’, Scientific Reports, 13(1). Available at: https://doi.org/10.1038/s41598-023-45171-7.

Isayeva, Ganna et al. (2023) ‘Diagnostic and prognostic value of H-ficolin for functionally relevant coronary artery disease’, Clinica Chimica Acta, 551. Available at: https://doi.org/10.1016/j.cca.2023.117582.

Gross, Sebastian et al. (2023) ‘Occurrence of sensitive topics during ward round: An ancillary analysis of the BEDSIDE-OUTSIDE trial’, BMJ Open, 13(9). Available at: https://doi.org/10.1136/bmjopen-2023-073584.

Breillat P et al. (2023) ‘Cutaneous vasculitis occurring in the setting of systemic lupus erythematosus: a multicentre cohort study’, Rheumatology (United Kingdom), 62(6), pp. 2189–2196. Available at: https://doi.org/10.1093/rheumatology/keac566.

Kleer, Jessica S. et al. (2023) ‘Complement C1s deficiency in a male Caucasian patient with systemic lupus erythematosus: a case report’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1257525.

Rabatscher, P. (2023) Immunological consequences of C1q and anti-c1q immune complexes in secondary cellular inflammation. Doctoral Thesis.

Schulz, Kristina et al. (2023) ‘Complement C1q and von Willebrand factor interaction in atherosclerosis of human carotid artery’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1265387.

Schulz, Kristina et al. (2023) ‘Complement C1q and von Willebrand factor interaction in atherosclerosis of human carotid artery’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1265387.

Urwyler, Pascal et al. (2023) ‘Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1255292.

Urwyler, Pascal et al. (2022) ‘Targeting thromboinflammation in COVID-19 – A narrative review of the potential of C1 inhibitor to prevent disease progression’, Molecular Immunology, 150, pp. 99–113. Available at: https://doi.org/10.1016/j.molimm.2022.08.008.

Bruni F et al. (2022) ‘Complement and endothelial cell activation in COVID-19 patients compared to controls with suspected SARS-CoV-2 infection: A prospective cohort study’, Frontiers in Immunology, 13, p. 941742. Available at: https://doi.org/10.3389/fimmu.2022.941742.

Schulz K. and Trendelenburg M. (2022) ‘C1q as a target molecule to treat human disease: What do mouse studies teach us?’, Frontiers in Immunology, 13. Available at: https://doi.org/10.3389/fimmu.2022.958273.

Capoferri G et al. (2022) ‘Cutaneous leukocytoclastic vasculitis secondary to COVID-19 infection leading to extensive skin necrosis’, Clinics in Dermatology, 40(4), pp. 397–401. Available at: https://doi.org/10.1016/j.clindermatol.2022.02.013.

Costa A.E. et al. (2022) ‘Severe myopathy complicating multisystem inflammatory syndrome in adults (MIS-A) in a young man’, BMJ Case Reports, 15(7). Available at: https://doi.org/10.1136/bcr-2022-250054.

Huebner, Simona Tabea et al. (2022) ‘Prediction of Acute COPD Exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by Clinical Parameters, Medication Use, and Immunological Biomarkers’, Respiration, 101(5), pp. 441–454. Available at: https://doi.org/10.1159/000520196.

Gross S et al. (2022) ‘Perception of physicians and nursing staff members regarding outside versus bedside ward rounds: Ancillary analysis of the randomised BEDSIDE-OUTSIDE trial’, Swiss Medical Weekly, 152(3-4). Available at: https://doi.org/10.4414/smw.2022.w30112.

Kleer JS et al. (2022) ‘Epitope-Specific Anti-C1q Autoantibodies in Systemic Lupus Erythematosus’, Frontiers in Immunology, 12, p. 761395. Available at: https://doi.org/10.3389/fimmu.2021.761395.

Chasset F. et al. (2022) ‘Serum interferon-α levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity’, Annals of the Rheumatic Diseases, 81(6), pp. 901–903. Available at: https://doi.org/10.1136/annrheumdis-2021-221835.

Rabatscher P.A. and Trendelenburg M. (2022) ‘Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40–CD154-mediated inflammation in peripheral blood mononuclear cells in vitro’, Clinical and Translational Immunology, 11(8). Available at: https://doi.org/10.1002/cti2.1408.

Urwyler, Pascal et al. (2021) ‘Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)’, Trials, 22(1). Available at: https://doi.org/10.1186/s13063-020-04976-x.

Vogt S et al. (2021) ‘Association of mannose-binding lectin, ficolin-2 and immunoglobulin concentrations with future exacerbations in patients with chronic obstructive pulmonary disease: secondary analysis of the randomized controlled REDUCE trial’, Respiratory Research, 22(1), p. 227. Available at: https://doi.org/10.1186/s12931-021-01822-9.

Charitos P. et al. (2021) ‘Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study’, Frontiers in Immunology, 12. Available at: https://doi.org/10.3389/fimmu.2021.765330.

Becker C et al. (2021) ‘Effect of bedside compared with outside the room patient case presentation on patients” knowledge about their medical care: A randomized, controlled, multicenter trial’, Annals of Internal Medicine, 174(9), pp. 1282–1292. Available at: https://doi.org/10.7326/M21-0909.

Kiener S. et al. (2021) ‘Variants affecting the C-terminal tail of UNC93B1 are not a common risk factor for systemic lupus erythematosus’, Genes, 12(8). Available at: https://doi.org/10.3390/genes12081268.

Mihailovic, J. et al. (2021) ‘Worse Cardiovascular and Renal Outcome in Male SLE Patients: First Gender Study From the Swiss SLE Cohort Study’. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-645732/v1.

Bertschi, Jasmin (2021) The impact of monocytes on CD3/D28 activated T cells upon anti-C1q autoantibody encounter. Masterarbeit.

Csorba K. et al. (2021) ‘Anti-C1q Autoantibodies: Standard Quantification and Innovative ELISA’, in Methods in Molecular Biology. Humana Press Inc. (Methods in Molecular Biology), pp. 107–114. Available at: https://doi.org/10.1007/978-1-0716-1016-9_10.

Trendelenburg M. (2021) ‘Autoantibodies against complement component C1q in systemic lupus erythematosus’, Clinical and Translational Immunology, 10(4). Available at: https://doi.org/10.1002/cti2.1279.

Kieninger-Gräfitsch A et al. (2020) ‘No association of complement mannose-binding lectin deficiency with cardiovascular disease in patients with Systemic Lupus Erythematosus’, Scientific Reports, 10(1), p. 3693. Available at: https://doi.org/10.1038/s41598-020-60523-3.

Chasset F et al. (2020) ‘Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers’, Rheumatology (United Kingdom), 59(11), pp. 3468–3478. Available at: https://doi.org/10.1093/rheumatology/keaa167.

Strasser DS et al. (2020) ‘Preclinical to clinical translation of cenerimod, a novel S1P 1 receptor modulator, in systemic lupus erythematosus’, RMD Open, 6(2). Available at: https://doi.org/10.1136/rmdopen-2020-001261.

Urwyler, Pascal et al. (2020) ‘Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System’, Frontiers in Immunology, 11. Available at: https://doi.org/10.3389/fimmu.2020.02072.

Donat C et al. (2020) ‘Complement C1q Enhances Primary Hemostasis’, Frontiers in Immunology, 11, p. 1522. Available at: https://doi.org/10.3389/fimmu.2020.01522.

Sarcevic J et al. (2020) ‘Case Report—Secondary Antibody Deficiency Due to Endogenous Hypercortisolism’, Frontiers in Immunology. Frontiers Media S.A., 11. Available at: https://doi.org/10.3389/fimmu.2020.01435.

Panagiotou A et al. (2020) ‘A Randomized Trial of Recombinant Human C1-Esterase-Inhibitor in the Prevention of Contrast-Induced Kidney Injury’, JACC: Cardiovascular Interventions, 13(7), pp. 833–842. Available at: https://doi.org/10.1016/j.jcin.2019.11.021.

Nigolian H et al. (2020) ‘Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus’, Rheumatology (United Kingdom), 59(3), pp. 534–544. Available at: https://doi.org/10.1093/rheumatology/kez306.

Donat, C. (2020) Immunological and functional consequences of von Willebrand factor binding to complement C1q. Doctoral Thesis. Available at: https://doi.org/10.5451/unibas-007198268.

Sarcevic, Jelena et al. (2020) ‘Secondary Antibody Deficiency Due to Endogenous Hypercortisolism’, Frontiers in Immunology, 11, p. 1435. Available at: https://doi.org/10.3389/fimmu.2020.01435.

Vogt, Severin et al. (2020) ‘Local and Systemic Concentration of Pattern Recognition Receptors of the Lectin Pathway of Complement in a Cohort of Patients With Interstitial Lung Diseases’, Frontiers in Immunology, 11, p. 562564. Available at: https://doi.org/10.3389/fimmu.2020.562564.

von Rotz, M. et al. (2019) ‘Aussergewöhnliche Ursache von Rückenschmerzen’, Swiss Medical Forum ‒ Schweizerisches Medizin-Forum [Preprint]. Available at: https://doi.org/10.4414/smf.2019.08340.

Donat C, Thanei S and Trendelenburg M (2019) ‘Binding of von Willebrand Factor to Complement C1q Decreases the Phagocytosis of Cholesterol Crystals and Subsequent IL-1 Secretion in Macrophages’, Frontiers in Immunology, 10, p. 2712. Available at: https://doi.org/10.3389/fimmu.2019.02712.

Friebus-Kardash J et al. (2019) ‘Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis’, BMC Nephrology, 20(1), p. 430. Available at: https://doi.org/10.1186/s12882-019-1623-4.

Csorba K et al. (2019) ‘Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site’, Frontiers in Immunology, 10, p. 2619. Available at: https://doi.org/10.3389/fimmu.2019.02619.

Troldborg A et al. (2019) ‘Ficolin-3 Deficiency Is Associated with Disease and an Increased Risk of Systemic Lupus Erythematosus’, Journal of Clinical Immunology, 39(4), pp. 421–429. Available at: https://doi.org/10.1007/s10875-019-00627-2.

Pröbstel AK et al. (2019) ‘Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus’, Rheumatology (United Kingdom), 58(5), pp. 908–913. Available at: https://doi.org/10.1093/rheumatology/key282.

Osthoff M et al. (2019) ‘Role of lectin pathway complement proteins and genetic variants in organ damage and disease severity of systemic sclerosis: A cross-sectional study’, Arthritis Research and Therapy, 21(1). Available at: https://doi.org/10.1186/s13075-019-1859-1.

Nehring J et al. (2018) ‘Autoantibodies against Albumin in patients with systemic lupus erythematosus’, Frontiers in Immunology. 02.10.2018, 9(OCT), p. 2090. Available at: https://doi.org/10.3389/fimmu.2018.02090.

Burkard T et al. (2018) ‘The heart in systemic lupus erythematosus – A comprehensive approach by cardiovascular magnetic resonance tomography’, PLoS ONE, 13(10), p. e0202105. Available at: https://doi.org/10.1371/journal.pone.0202105.

Marchetti T et al. (2018) ‘Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus’, Rheumatology (United Kingdom), 57(8), pp. 1350–1357. Available at: https://doi.org/10.1093/rheumatology/key095.

Troldborg A et al. (2018) ‘The lectin pathway of complement activation in patients with systemic lupus erythematosus’, Journal of Rheumatology. 15.06.2018, 45(8), pp. 1136–1144. Available at: https://doi.org/10.3899/jrheum.171033.

Panagiotou A, Trendelenburg M and Osthoff M (2018) ‘The Lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor’, Frontiers in Immunology, 9(MAY), p. 1151. Available at: https://doi.org/10.3389/fimmu.2018.01151.

Dahdal S et al. (2018) ‘Serum calcification propensity is independently associated with disease activity in systemic lupus erythematosus’, PLoS ONE. 24.01.2018, 13(1), p. e0188695. Available at: https://doi.org/10.1371/journal.pone.0188695.

Friebus-Kardash J et al. (2018) ‘Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus’, Nephrology Dialysis Transplantation, 33(1), pp. 54–64. Available at: https://doi.org/10.1093/ndt/gfx220.

Trendelenburg, Marten et al. (2018) ‘Complement activation products in acute heart failure: Potential role in pathophysiology, responses to treatment and impacts on long-term survival’, European heart journal. Acute cardiovascular care, 7(4), pp. 348–357. Available at: https://doi.org/10.1177/2048872617694674.

Thanei S et al. (2017) ‘Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages’, Biochemical Pharmacology. 04.10.2017, 146, pp. 151–164. Available at: https://doi.org/10.1016/j.bcp.2017.10.001.

Osthoff M et al. (2017) ‘Association of Lectin Pathway Protein Levels and Genetic Variants Early after Injury with Outcomes after Severe Traumatic Brain Injury: A Prospective Cohort Study’, Journal of Neurotrauma, 34(17), pp. 2560–2566. Available at: https://doi.org/10.1089/neu.2016.4941.

Huber, Xaver et al. (2017) ‘Primary intestinal lymphangiectasia in an elderly female patient: A case report on a rare cause of secondary immunodeficiency.’, Medicine, 96(31), p. e7729. Available at: https://doi.org/10.1097/md.0000000000007729.

Kofler T et al. (2017) ‘[Abdominal pain and hypertension in a 55-year-old male patient].’, Der Internist, 58(4), pp. 397–401. Available at: https://doi.org/10.1007/s00108-016-0170-3.

Chaigne B et al. (2017) ‘Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS)’, BMC Immunology. 28.03.2017, 18(1), p. 17. Available at: https://doi.org/10.1186/s12865-017-0200-5.

Thanei S and Trendelenburg M (2017) ‘Anti-C1q autoantibodies from patients with systemic lupus erythematosus induce C1q production by macrophages’, Journal of Leukocyte Biology. 14.09.2016, 101(2), pp. 481–491. Available at: https://doi.org/10.1189/jlb.3A1215-535R.

Kolm, R. et al. (2016) ‘Von Willebrand Factor Interacts with Surface-Bound C1q and Induces Platelet Rolling’, J Immunol, 197(9), pp. 3669–3679. Available at: https://doi.org/10.4049/jimmunol.1501876.

Osthoff, Michael et al. (2016) ‘Association of lectin pathway proteins with intra-abdominal Candida infection in high-risk surgical intensive-care unit patients. A prospective cohort study within the fungal infection network of Switzerland’, The Journal of infection, 72(3), pp. 377–85. Available at: https://doi.org/10.1016/j.jinf.2015.12.011.

Thanei, S. and Trendelenburg, M. (2016) ‘Anti-C1q Autoantibodies from Systemic Lupus Erythematosus Patients Induce a Proinflammatory Phenotype in Macrophages’, J Immunol, 196(5), pp. 2063–74. Available at: https://doi.org/10.4049/jimmunol.1501659.

Vitkova, H. et al. (2016) ‘Anti-C1q autoantibodies are linked to autoimmune thyroid disorders in pregnant women’, Clin Exp Immunol, 186(1), pp. 10–7. Available at: https://doi.org/10.1111/cei.12813.

Stegert M, Bock M and Trendelenburg M (2015) ‘Clinical presentation of human C1q deficiency: How much of a lupus?’, Molecular Immunology, 67(1), pp. 3–11. Available at: https://doi.org/10.1016/j.molimm.2015.03.007.

Bock, Merete, Heijnen, Ingmar and Trendelenburg, Marten (2015) ‘Anti-C1q antibodies as a follow-up marker in SLE patients’, PLoS ONE, 10(4), p. e0123572. Available at: https://doi.org/10.1371/journal.pone.0123572.

Koenig, K. F. et al. (2015) ‘Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts’, Lupus, 24(1), pp. 58–65. Available at: https://doi.org/10.1177/0961203314550223.

Kölm, R. (2015) Von Willebrand factor binds surface-bound C1q and induces platelet rolling. Doctoral Thesis. Available at: https://doi.org/10.5451/unibas-006416108.

Mandal, Jyotshna et al. (2015) ‘Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study’, Respir Res, 16, p. 150. Available at: https://doi.org/10.1186/s12931-015-0306-3.

Pesickova, Satu Sinikka et al. (2015) ‘Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up’, Arthritis Research & Therapy, 17, p. 371. Available at: https://doi.org/10.1186/s13075-015-0879-8.

Thanei, S. (2015) Functional consequences of anti-C1q autoantibodies from systemic lupus erythematosus patients. Doctoral Thesis. Available at: https://doi.org/10.5451/unibas-006744624.

Thanei, Sophia, Vanhecke, Dominique and Trendelenburg, Marten (2015) ‘Anti-C1q autoantibodies from systemic lupus erythematosus patients activate the complement system via both the classical and lectin pathways’, Clinical Immunology, 160(2), pp. 180–7. Available at: https://doi.org/10.1016/j.clim.2015.06.014.

Ribi C et al. (2014) ‘The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - Cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland’, Swiss Medical Weekly. 07.08.2014, 144, p. w13990. Available at: https://doi.org/10.4414/smw.2014.13990.

Schifferli J.A. and Trendelenburg M. (2014) ‘Cryoglobulinemia and chronic HCV infection: An evolving story’. Springer-Verlag Italia s.r.l., pp. 79–83. Available at: https://doi.org/10.1007/978-88-470-1705-4_9.

Nytrova, Petra et al. (2014) ‘Complement activation in patients with neuromyelitis optica’, Journal of Neuroimmunology, 274(1-2), pp. 185–91. Available at: https://doi.org/10.1016/j.jneuroim.2014.07.001.

Potlukova E et al. (2013) ‘Association between low levels of mannan-binding lectin and markers of autoimmune thyroid disease in pregnancy’, PLoS ONE, 8(12), p. e81755. Available at: https://doi.org/10.1371/journal.pone.0081755.

Osthoff M and Trendelenburg M (2013) ‘Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction’, BioMed Research International, 2013(1), p. 962695. Available at: https://doi.org/10.1155/2013/962695.

Scharein P and Trendelenburg M (2013) ‘Critical incidents in a tertiary care clinic for internal medicine’, BMC Research Notes. 16.07.2013, 6(1), p. 276. Available at: https://doi.org/10.1186/1756-0500-6-276.

Trendelenburg, M. and Ribi, C. (2013) ‘Systemischer Lupus Erythematodes – die «Swiss SLE Cohort Study (SSCS)»’, Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 13(22). Available at: https://doi.org/10.4414/smf.2013.01532.

Egli, A. et al. (2013) ‘Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients’, PLoS ONE, 8(1), p. e51983. Available at: https://doi.org/10.1371/journal.pone.0051983.

Vanhecke D. et al. (2012) ‘Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay’, Arthritis and Rheumatism, 64(11), pp. 3706–3714. Available at: https://doi.org/10.1002/art.34605.

Osthoff M et al. (2012) ‘Impact of mannose-binding lectin deficiency on radiocontrast-induced renal dysfunction: A post-hoc analysis of a multicenter randomized controlled trial’, BMC Nephrology. 03.09.2012, 13(1), p. 99. Available at: https://doi.org/10.1186/1471-2369-13-99.

Trendelenburg M. (2012) ‘The complement system in cryoglobulinemia’. Springer-Verlag Italia s.r.l., pp. 85–89. Available at: https://doi.org/10.1007/978-88-470-1705-4_10.

Hirt-Minkowski, P. et al. (2012) ‘A trial of complement inhibition in a patient with cryoglobulin-induced glomerulonephritis’, Case Reports in Nephrology and Urology, 2(1), pp. 38–45. Available at: https://doi.org/10.1159/000339403.

Koenig, Katrin Franzika et al. (2012) ‘Serum cytokine profile in patients with active lupus nephritis’, Cytokine, 60(2), pp. 410–6. Available at: https://doi.org/10.1016/j.cyto.2012.07.004.

Koenig, K. F. et al. (2012) ‘MBL serum levels in patients with sepsis correlate with thyroid function but not with outcome’, Clinical Immunology, 144(1), pp. 80–2. Available at: https://doi.org/10.1016/j.clim.2012.05.002.

Trendelenburg M (2012) ‘Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis: Comment on the article by Katsumata et al’, 64(1). Available at: https://doi.org/10.1002/art.33384.

Osthoff M et al. (2011) ‘Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients’, PLoS ONE, 6(6). Available at: https://doi.org/10.1371/journal.pone.0021338.

Benz, Nadja et al. (2011) ‘Three cases of primary small vessel vasculitis of the skeletal muscle-an own entity’, BMJ case reports, 2011, p. Nov 8. Available at: https://doi.org/10.1136/bcr.08.2011.4631.

Bigler, Cornelia et al. (2011) ‘Anti-C1q autoantibodies do not correlate with the occurrence or severity of experimental lupus nephritis’, Nephrology, dialysis, transplantation, 26(4), pp. 1220–8. Available at: https://doi.org/10.1093/ndt/gfq558.

Osthoff, Michael et al. (2011) ‘Mannose-binding lectin - the forgotten molecule?’, Nature medicine, 17(12), p. 1547–8; author reply 1548. Available at: https://doi.org/10.1038/nm.2588.

Osthoff, M. et al. (2011) ‘Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients’, PLoS ONE, 6(6), p. e21338. Available at: https://doi.org/10.3410/f.717949101.793454250.

Knecht, Margrith E et al. (2010) ‘A patient with SLE-associated thrombotic microangiopathy and non-neutralizing antibodies against ADAMTS13.’, Nephrology, dialysis, transplantation, 25(5), pp. 1720–2. Available at: https://doi.org/10.1093/ndt/gfq021.